The new and evolving pharmacotherapy of schizophrenia (Q35102476)

6 August 2017

1 reference

title

The new and evolving pharmacotherapy of schizophrenia (English)

1 reference

6 August 2017

0 references

1 reference

Robin Emsley

1

1 reference

PubMed ID

12683264

6 August 2017

Piet Oosthuizen

series ordinal

2

1 reference

6 August 2017

1 March 2003

1 reference

Psychiatric Clinics of North America

6 August 2017

1 reference

6 August 2017

26

1 reference

6 August 2017

1

1 reference

6 August 2017

141-163

1 reference

The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus other atypical antipsychotic medication for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Early versus delayed initiation of progressive enteral feedings for parenterally fed low birth weight or preterm infants

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Quetiapine for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Molindone for schizophrenia and severe mental illness.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Sertindole for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Drug treatment of the negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Effects of risperidone on affective symptoms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Effect of risperidone on hostility in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

The new atypical antipsychotics: a review of pharmacoeconomic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900016-3

7 January 2021

10.1016/S0193-953X(02)00016-3

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12683264